INS and type 2 diabetes mellitus: The present study suggests similar efficacy profiles between the NPH insulin formulations Humulin and Gansulin in the treatment of patients with T2DM, which therefore indicates the possibility of introducing a new commercial form of human NPH insulin in addition to the preparations already used in public and private systems, with a possible reduction in costs.